StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:EGRX opened at $0.64 on Thursday. The firm has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $2.60. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently made changes to their positions in EGRX. Vanguard Personalized Indexing Management LLC acquired a new stake in Eagle Pharmaceuticals in the second quarter worth $76,000. XTX Topco Ltd acquired a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth about $113,000. Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at about $71,000. Cubist Systematic Strategies LLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter valued at about $145,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $65,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.